Improving existing means of sentinel lymph node identification in non-small cell lung cancer will allow for molecular detection of occult micrometastases that may cause recurrence in early stage non-small cell lung cancer. Furthermore, targeted application of chemical and biological cytotoxic agents can potentially improve outcomes in patients with lymph node (LN) metastases. “Therapeutic Sentinel Lymph Node Imaging” incorporates these modalities into a single agent thereby identifying which LNs harbor tumor cells and simultaneously eradicating metastatic disease. In this review, we summarize the novel preclinical agents for identification and treatment of tumor bearing LNs and discuss their potential for clinical translation.
Division of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
Address reprint requests to Prasad S. Adusumilli, MD, Division of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065
Supported in part by AACR-AstraZeneca Lung Cancer Translational Research Grant, AATS-Third Edward D. Churchill Research Scholarship, IASLC−International Association for the Study of Lung Cancer Young Investigator Award, and National Lung Cancer Partnership/LUNGevity Foundation Research Grants.
ABSTRACT